<source id="3oodw" ><sup id="3oodw" ></sup></source>

      1. <s id="3oodw" ><th id="3oodw" ><small id="3oodw" ></small></th></s>
        <i id="3oodw" ><optgroup id="3oodw" ></optgroup></i>

            <input id="3oodw" ><bdo id="3oodw" ><cite id="3oodw" ></cite></bdo></input>
            <delect id="3oodw" ><ruby id="3oodw" ></ruby></delect>

            <em id="3oodw" ><progress id="3oodw" ></progress></em><input id="3oodw" ></input>
            <strike id="3oodw" ></strike>
            India

            USA: Strategic Partnership

            Biomotiv and Bristol-Myers Squibb Launch New Biotech 河南幸运彩走势图app

            | Editor: Alexander Stark

            Biomotiv and Bristol-Myers Squibb have announced the launch of Anteros Pharmaceuticals.
            Gallery: 1 image
            Biomotiv and Bristol-Myers Squibb have announced the launch of Anteros Pharmaceuticals. (Source: Public Domain / )

            Biomotiv and Bristol-Myers Squibb 河南幸运彩走势图app announced the launch of Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

            New York/USA — Biomotiv and Bristol-Myers Squibb have executed a Strategic Partnership Agreement in September 2019. Now, the partners have launched a first company, called Anteros Pharmaceuticals. It is the first of several companies that the two companies intend to form under the Strategic Partnership Agreement. The intellectual property behind Anteros was first developed by Yale University and in-licensed by Bristol-Myers Squibb and subsequently assigned to Anteros. According to Satish Jindal, Ph.D., Biomotiv’s CEO, Anteros will focus on refining a new class of drug candidates for inflammatory diseases, where currently there are no real answers to multiple diseases that afflict millions of patients.

            Under the terms of the partnership, Bristol-Myers Squibb will contribute the IP, data, and reagents for a series of small molecules against an undisclosed mechanism, and Biomotiv, through the formation of Anteros Pharmaceuticals, working in close partnership with Yale, will be solely responsible for research and development. Once Anteros nominates a pre-clinical candidate, Bristol-Myers Squibb has the option to acquire the company from Biomotiv under pre-agreed terms.

            Comments are being loaded ....

            Leave a comment

            The comment is checked by an editor and will be released soon.

            1. Avatar
              Avatar
              Edited by at
              Edited by at
              1. Avatar
                Avatar
                Edited by at
                Edited by at

            Comments are being loaded ....

            Report comment

            Kommentar Freigeben

            Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

            Freigabe entfernen

            Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

            copyright

            This article is protected by copyright. You want to use it for your own purpose? Contact us via: (ID: 46352702 / Pharma & Food)